Interferon-gamma release assay and Rifampicin therapy for household contacts of tuberculosis

Journal of Infection

Volumn 64, Issue 3, 2012, Pages 291-298

  Wang, Jann Yuan ^a   Shu, Chin Chung ^a   Lee, Chih Hsin ^b   Yu, Chong Jen ^a   Lee, Li Na ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Household contact; Latent tuberculosis infection; Pulmonary tuberculosis; Risk factor; T SPOT.TB; Taiwan

Indexed keywords

RIFAMPICIN;

ADULT; ARTICLE; BACTERIUM CONTAMINATION; CONTACT EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LONGITUDINAL STUDY; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYNDROME DELINEATION; TREATMENT DURATION;

ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; CONTACT TRACING; FAMILY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; PROGNOSIS; RIFAMPIN; RISK FACTORS; TUBERCULOSIS;

EID: 84856598035     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.11.028     Document Type: Article

References (30)

1. Styblo K. Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 1980, 20:1-63.
2. Centers for Disease Control and Prevention Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995, 44(RR-11):1-16.
3. Menzies D., Pai M., Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007, 146(5):340-354.
4. Chegou N.N., Black G.F., Kidd M., van Helden P.D., Walzl G. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009, 9:21.
5. Kobashi Y., Mouri K., Yagi S., Obase Y., Miyashita N., Oka M. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect 2009, 58(3):197-204.
6. Chee C.B., KhinMar K.W., Gan S.H., Barkham T.M., Koh C.K., Shen L., et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010, 36(2):355-361.
7. Bocchino M., Chairadonna P., Matarese A., Bruzzese D., Salvatores M., Tronci M., et al. Limited usefulness of QuantiFERON-TB Gold In-Tube for monitoring anti-tuberculosis therapy. Respir Med 2010, 104(10):1551-1556.
8. Anonymous Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS board of directors, July 1999. This is a Joint statement of the American Thoracic Society (ATS) and the centers for disease control and prevention (CDC). This statement was endorsed by the Council of the infectious diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000, 161(4 Pt 2):S221-S247.
9. Leung C.C., Rieder H.L., Lange C., Yew W.W. Treatment of latent infection with M. tuberculosis: update 2010. Eur Respir J 2010.
10. Anonymous A. double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992, 145(1):36-41.
11. Polesky A., Farber H.W., Gottlieb D.J., Park H., Levinson S., O'Connell J.J., et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996, 154(5):1473-1477.
12. Villarino M.E., Ridzon R., Weismuller P.C., Elcock M., Maxwell R.M., Meador J., et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997, 155(5):1735-1738.
13. Page K.R., Sifakis F., Montes de Oca R., Cronin W.A., Doherty M.C., Federline L., et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006, 166(17):1863-1870.
14. Lardizabal A., Passannante M., Kojakali F., Hayden C., Reichman L.B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006, 130(6):1712-1717.
15. Haley C.A., Stephan S., Vossel L.F., Sherfy E.A., Laserson K.F., Kainer M.A. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis 2008, 12(2):160-167.
16. Menzies D., Dion M.J., Rabinovitch B., Mannix S., Brassard P., Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004, 170(4):445-449.
17. Menzies D., Long R., Trajman A., Dion M.J., Yang J., Al Jahdali H., et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008, 149(10):689-697.
18. Farhat M., Greenaway C., Pai M., Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 2006, 10(11):1192-1204.
19. Chang F.Y., Shi W.Y., Ling T., Chou J.H., Chen Y.H., Chuang J.H., et al. Taiwan tuberculosis control report 2010 2010, Centers for Disease Control, Department of Health, Taipei, R.O.C., Taiwan. 4th ed.
20. Jeong Y.J., Lee K.S. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol 2008, 191(3):834-844.
21. Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167(4):603-662.
22. Diel R., Loddenkemper R., Meywald-Walter K., Niemann S., Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008, 177(10):1164-1170.
23. Diel R., Nienhaus A., Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007, 131(5):1424-1434.
24. Deuffic-Burban S., Atsou K., Viget N., Melliez H., Bouvet E., Yazdanpanah Y. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 2010, 14(4):471-481.
25. Pai M., Joshi R., Dogra S., Mendiratta D.K., Narang P., Kalantri S., et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006, 174(3):349-355.
26. Ewer K., Millington K.A., Deeks J.J., Alvarez L., Bryant G., Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006, 174(7):831-839.
27. Franken W.P., Arend S.M., Thijsen S.F., Bouwman J.J., Koster B.F., van Dissel J.T., et al. Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts. Int J Tuberc Lung Dis 2008, 12(11):1286-1294.
28. Andersen P., Munk M.E., Pollock J.M., Doherty T.M. Specific immune-based diagnosis of tuberculosis. Lancet 2000, 356(9235):1099-1104.
29. Arend S.M., van Meijgaarden K.E., de Boer K., de Palou E.C., van Soolingen D., Ottenhoff T.H., et al. Tuberculin skin testing and invitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 2002, 186(12):1797-1807.
30. Lai C.C., Tan C.K., Chou C.H., Hsu H.L., Liao C.H., Huang Y.T., et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis 2010, 16(2):294-296.